Breast cancer homologous recombination deficiency prediction from pathological images with a sufficient and representative Transformer
Abstract Homologous recombination deficiency (HRD) has been recognized as a key biomarker for poly-ADP ribose polymerase inhibitors (PARPi) and platinum-based chemotherapy in breast cancer (BC). HRD prediction typically relies on molecular biology assays, which have a high turnaround time, and cost....
Saved in:
| Main Authors: | Haijing Luan, Taiyuan Hu, Jifang Hu, Weier Liu, Kaixing Yang, Yue Pei, Ruilin Li, Jiayin He, Yajun Gao, Dawei Sun, Xiaohong Duan, Rui Yan, S. Kevin Zhou, Beifang Niu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-00950-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers
by: Qiuyang Xu, et al.
Published: (2025-08-01) -
Analysis of homologous recombination deficiency in prostate cancer
by: A. G. Iyevleva, et al.
Published: (2025-03-01) -
Leveraging homologous recombination repair deficiency in sarcoma
by: Dea Slade, et al.
Published: (2023-03-01) -
Homologous recombination deficiency among patients with germline or somatic non-BRCA1/2 homologous recombination repair gene variations
by: Yue Li, et al.
Published: (2025-06-01) -
The impact of homologous recombination deficiency on the prognosis of epithelial ovarian cancer
by: Haiqi Su, et al.
Published: (2025-01-01)